NRD
OPRX icon

Nebula Research & Development’s OptimizeRx OPRX Stock Holding History

Nebula Research & Development’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,675
Closed -$195K – 619
2023
Q2 		$195K Sell
13,675
-8,450
-38% -$120K 0.15% 273
2023
Q1 		$324K Buy
+22,125
New +$370K 0.57% 2

Other funds holding OPRX

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return

Nebula Research & Development's OPRX Position: Q3 2023 in Review

Nebula Research & Development sold out of OptimizeRx (OPRX) in Q3 2023, closing a stake of 13,675 shares — an estimated $195K sold.

Nebula Research & Development first reported a position in OPRX in Q1 2023 and held it in 2 quarters. The position peaked at $324K in Q1 2023. 94 funds tracked by Wall St. Rank hold OPRX as of Q3 2023.

  • Nebula Research & Development reported no remaining OptimizeRx position as of Q3 2023 after selling out during the quarter.
  • Nebula Research & Development sold 13,675 OptimizeRx shares in Q3 2023, an estimated $195K.
  • Nebula Research & Development first reported a position in OptimizeRx in Q1 2023 and held it in 2 quarters.
  • Nebula Research & Development's OptimizeRx position peaked at $324K in Q1 2023.
  • 94 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2023.

Based on Nebula Research & Development's 13F filing for Q3 2023, filed 14 Nov 2023.